Christopher  Patusky net worth and biography

Christopher Patusky Biography and Net Worth

Director of United Therapeutics
Mr. Patusky has more than 30 years of experience in the private, public and nonprofit sectors. After graduating from Harvard Law School, he clerked and practiced law from 1988 to 2000, focusing on litigation, intellectual property, and business startup. His legal work included co-leading a team that obtained the first approval from the Federal Communications Commission and the United Nation's International Telecommunications Union of the use of stratospheric stations for delivery of telecommunication services worldwide. After receiving a master’s degree in governmental administration from the University of Pennsylvania in 2001, Mr. Patusky served from 2002 to 2007 as the Executive Director and member of the faculty of the University of Pennsylvania’s Fels Institute of Government. At Fels, he created and led the implementation of a first of its kind performance management system for the 270 schools of the Philadelphia School District, which was awarded an IBM Business of Government Award. From 2007 to 2011, Mr. Patusky was the Director of the Office of Real Estate and as a member of the Senior Policy Team at the Maryland Department of Transportation where he served on the Secretary's sustainability committee while focusing his efforts on the Governor's Transit Oriented Development (TOD) policy initiative, including drafting and lobbying passage of the Maryland TOD law, the authority he then used to advance real estate developments adjacent to Maryland's transit stations. Since 2012, Mr. Patusky has served as the founding principal of Patusky Associates, LLC, which serves as a personal investment vehicle, and as an executive manager of Slater Run Vineyards, LLC, his family’s farm-based vineyard and winery.

What is Christopher Patusky's net worth?

The estimated net worth of Christopher Patusky is at least $1,097.04 as of February 23rd, 2024. Mr. Patusky owns 4 shares of United Therapeutics stock worth more than $1,097 as of May 19th. This net worth approximation does not reflect any other investments that Mr. Patusky may own. Learn More about Christopher Patusky's net worth.

How do I contact Christopher Patusky?

The corporate mailing address for Mr. Patusky and other United Therapeutics executives is 1040 SPRING ST, SILVER SPRING MD, 20910. United Therapeutics can also be reached via phone at (301) 608-9292 and via email at [email protected]. Learn More on Christopher Patusky's contact information.

Has Christopher Patusky been buying or selling shares of United Therapeutics?

During the past quarter, Christopher Patusky has sold $346,298.50 in United Therapeutics stock. Most recently, Christopher Patusky sold 1,310 shares of the business's stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $264.35, for a transaction totalling $346,298.50. Learn More on Christopher Patusky's trading history.

Who are United Therapeutics' active insiders?

United Therapeutics' insider roster includes Christopher Causey (Director), Raymond Dwek (Director), Paul Mahon (EVP), Nilda Mesa (Director), Judy Olian (Director), Christopher Patusky (Director), Martine Rothblatt (CEO), and Louis Sullivan (Director). Learn More on United Therapeutics' active insiders.

Are insiders buying or selling shares of United Therapeutics?

During the last twelve months, insiders at the biotechnology company sold shares 43 times. They sold a total of 246,628 shares worth more than $57,765,224.98. The most recent insider tranaction occured on May, 14th when Director Christopher Patusky sold 1,310 shares worth more than $346,298.50. Insiders at United Therapeutics own 12.5% of the company. Learn More about insider trades at United Therapeutics.

Information on this page was last updated on 5/14/2024.

Christopher Patusky Insider Trading History at United Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/14/2024Sell1,310$264.35$346,298.50View SEC Filing Icon  
2/23/2024Sell1,680$224.00$376,320.004View SEC Filing Icon  
4/20/2023Buy6$114.06$684.361,686View SEC Filing Icon  
3/20/2023Sell5$107.71$538.551,680View SEC Filing Icon  
11/8/2021Sell2,300$200.16$460,368.00View SEC Filing Icon  
5/10/2021Sell100$190.52$19,052.004,800View SEC Filing Icon  
3/7/2019Sell3,370$110.75$373,227.50View SEC Filing Icon  
1/12/2017Sell5,000$141.99$709,950.005,000View SEC Filing Icon  
11/10/2016Sell5,000$131.42$657,100.005,000View SEC Filing Icon  
9/1/2016Sell5,000$122.73$613,650.005,000View SEC Filing Icon  
1/8/2015Sell5,000$128.13$640,650.00View SEC Filing Icon  
11/7/2014Sell5,000$124.49$622,450.00View SEC Filing Icon  
8/7/2014Sell5,000$88.23$441,150.00View SEC Filing Icon  
5/8/2014Sell5,000$107.17$535,850.00View SEC Filing Icon  
3/6/2014Sell5,000$101.39$506,950.00View SEC Filing Icon  
1/9/2014Sell5,000$110.00$550,000.00View SEC Filing Icon  
11/14/2013Sell5,500$91.65$504,075.00View SEC Filing Icon  
11/7/2013Sell3,500$90.51$316,785.00View SEC Filing Icon  
9/5/2012Sell2,000$55.47$110,940.00View SEC Filing Icon  
See Full Table

Christopher Patusky Buying and Selling Activity at United Therapeutics

This chart shows Christopher Patusky's buying and selling at United Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

United Therapeutics Company Overview

United Therapeutics logo
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Read More

Today's Range

Now: $274.26
Low: $270.26
High: $274.48

50 Day Range

MA: $244.01
Low: $228.26
High: $274.26

2 Week Range

Now: $274.26
Low: $204.44
High: $275.00

Volume

329,200 shs

Average Volume

461,333 shs

Market Capitalization

$12.17 billion

P/E Ratio

12.97

Dividend Yield

N/A

Beta

0.54